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Both Parkin and UBE3A are E3 ubiquitin ligases whose mutations result in severe brain dysfunction. Several of their substrates
have been identified using cell culture models in combination with proteasome inhibitors, but not in more physiological settings.
We recently developed the bioUb strategy to isolate ubiquitinated proteins in flies and have now identified by mass spectrometry
analysis the neuronal proteins differentially ubiquitinated by those ligases. This is an example of how flies can be used to provide
biological material in order to reveal steady state substrates of disease causing genes. Collectively our results provide new leads to
the possible physiological functions of the activity of those two disease causing E3 ligases. Particularly, in the case of Parkin the
novelty of our data originates from the experimental setup, which is not overtly biased by acute mitochondrial depolarisation. In
the case of UBE3A, it is the first time that a nonbiased screen for its neuronal substrates has been reported.
1. Introduction
Both Parkin (PARK2) andUBE3A are E3 ubiquitin ligases for
which mutations result in severe brain dysfunction, Familial
Parkinson’s Disease (PD), and Angelman Syndrome (AS).
In order to unravel the molecular mechanisms leading to
these neurological dysfunctions it is necessary to identify
and understand the role of their ubiquitinated substrates.
Several substrates of UBE3A and Parkin have been surveyed
mostly using cell culture overexpression models in com-
bination with proteasome inhibitors. But more recently, a
more physiological setting has been achieved by using an in
vivo biotinylation strategy to isolate ubiquitinated proteins
from Drosophila brains. With a label-free mass spectrometry
approach, in order to quantify ubiquitinated proteins, we
detected substrates of these two E3 ligases inDrosophila. This
is an example of how flies can be used to reveal physiological
substrates of disease-associated proteins. The results, using
Drosophila as a validated model for neuronal disorders,
provide new leads towards the cellular roles of these two
disease causing E3 ligases.
2. Intracellular Proteostatic
Quality Control Mechanisms:
The Ubiquitin-Proteasome
System (UPS) and Autophagy
The human genome contains ∼20.000 protein-coding genes
[1], but the set of proteins (proteome) present in a given cell
is specifically determined in a cell type and developmental
manner [2, 3]. Currently, the deepest proteomic coverage
has identified about 12,000 proteins in mice brain samples
[4]. In order to adapt their proteomes according to cellular
requirements and warrant appropriate fitness of proteins,
cells differentially express and regulate their genome through
interconnected pathways of protein synthesis and distinct
quality control mechanisms [5]. A plethora of cofactors
and chaperones supports newly synthesised proteins to
ensure their correct folding into fully functional three-
dimensional structures [5]. This is a critical process not
only to maintain physiological proteostasis but also to avoid
the appearance of toxic protein aggregates [6]. However,
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even when proteins are correctly folded and functionally
active in their final compartment, various factors can desta-
bilise the proteins and irreversibly impair them. For this
purpose, cells possess quality control mechanisms such as
the Ubiquitin-Proteasome System (UPS) and autophagy
that specifically degrade damaged proteins and organelles
[7, 8].
Ubiquitin (Ub) is a small protein (∼8.5 kDa) that is
specifically attached to target proteins through a sequential
enzymatic cascade [7]. Classically, Ub-activating E1 enzymes
activate and transfer Ub to Ub-carrier E2 enzymes, which
finally covalently modify the target proteins with Ub with the
assistance of Ub-ligase E3 enzymes (Figure 1(a)). As is the
case with other posttranslational modifications (PTMs), such
as phosphorylation, ubiquitination is a reversible process.
A fourth family of proteins, called deubiquitinases (DUBs),
has the ability to cleave Ub moieties from their substrate
proteins, acting as editors and recycling the free Ub pool.
Conjugation of a single ubiquitin can be performed to a
certain lysine of the target protein (monoubiquitination), or
to several lysines simultaneously (multimonoubiquitination).
Additionally ubiquitin can also be attached to another pre-
assembled ubiquitin through the N-terminal, or any of its
seven internal lysines, building chains (polyubiquitination)
of different topology. Depending on which residue of the
next ubiquitin is modified, M1, K6, K11, K27, K29, K33,
K48, or K63 polyubiquitin chains can be formed. Com-
binations of alternate lysine residues can result in mixed
ubiquitin chains too. Additionally, chains can be branched
by other ubiquitin chains. Taken together, all these pos-
sible modifications result in a highly diverse set of chain
types and ubiquitination types, each of which will have a
different readout by the cell, the so-called “ubiquitin code”
[9]. Due to this versatility of ubiquitin, the complexity of
the UPS is extremely high and is not limited to play a
role in protein degradation. Instead, UPS is essential in a
plethora of additional key biological processes (Figure 1(a)),
including receptor endocytosis and endosomal trafficking
[10], cellular progression and chromosome reassembly, tran-
scriptional regulation, signal transduction, and apoptosis
[9].
Autophagy refers to the process in which cells engulf their
own contents into double-membrane structures (autophago-
somes) that ultimately fuse with lysosomes, where cargo
is degraded and basic biomolecules are recycled back to
the cytosol (Figure 1(b)) [8]. Large cytosolic contents or
organelles are typically wrapped into a double membrane
(isolation membrane) that expands engulfing cargo into
autophagosomes (macroautophagy) [11]. Smaller cytosolic
cargo is instead taken up by direct lysosomal invagina-
tion (microautophagy) [12], whereas unfolded or aggre-
gated proteins are translocated into the lysosomal lumen
by chaperone-mediated autophagy [13]. Interestingly, ubiq-
uitination is also involved in the regulation of autophagy
[14–19]. In addition to its other roles, therefore, it is
clear that ubiquitination serves as universal tag for sub-
strate degradation, as all intracellular degradation path-
ways appear to be interconnected and governed by it
[20].
3. The UPS Is Essential for Correct
Neuronal Homeostasis
Neurons particularly require a tight spatiotemporal regula-
tion of their proteome. The cell body or soma is typically
distant from axonal and synaptic connections; and they are
constantly receiving, decoding, and transmitting information
via synaptic communication. Regulation of protein interac-
tion, sorting, and activity is not only critical for the wellbeing
of the neuron itself, but it is also necessary for proper
coordinated transfer of the information. Thus, right balance
between protein synthesis and degradation is essential for
neuronal homeostasis, both for correct neurodevelopment
and, at later stages in aged neurons, to protect against
stochastic proteotoxicity [21].
The first evidence of the involvement of the UPS in
the nervous system homeostasis came from the discovery
that ubiquitin is present in neurofibrillary tangles of various
neurodegenerative diseases [22, 23]. Hereafter, a variety of
failures at different levels of the UPS have been linked to
several neurodevelopmental and neurodegenerative diseases.
For instance, mutations in the UBA1 activating E1 enzyme are
associated with X-linked Infantile Spinal Muscular Atrophy
[24], whereas UBE2K E2 enzyme has been implicated in the
pathogenesis of Huntington’s disease [25, 26] andAlzheimer’s
disease [27]. UBE2H enzyme is associated with autism [28]
and loss of Parkin and UBE3A ligase activity is linked to
autosomal recessive juvenile parkinsonism and Angelman
Syndrome, respectively [29, 30]. Similarly, downregulation of
the DUB enzyme UCHL1 has also been linked with Parkin-
son’s and Alzheimer’s disease [31, 32]. Additionally, variants
of the Ubiquilin1 (UBQLN1) ubiquitin receptor protein are
associated with a higher risk of developing Alzheimer’s
disease [33], whereas disruption of the Rpt2 subunit of the
proteasome in mice has been reported to be enough to
trigger PD-like neurodegeneration [34]. Ubiquitin-mediated
degradation and signalling are of outstanding importance for
adequate neuronal function and development. Ubiquitina-
tion regulates processes such as neurite growth and guidance
[35], synaptic maturation and neurotransmitter release [36,
37], and neurotransmitter receptor internalisation [38] and it
is even imperative for neurogenesis to successfully take place
[39].
Drosophila has been a valuable tool to shed light on our
understanding of the role of ubiquitination in the nervous
system. In fact, evidence of a link between UPS and synapse
formation has often come first from experiments performed
in flies. For example, in the early 90s, the fat facets (faf)
gene was found to encode a DUB involved in fly eye
development [40, 41], while the E2 enzyme coding bendless
gene was shown to regulate neuronal connectivity [42, 43].
Fly mutants of the E3 ligase gene highwirewere later reported
to have a defective synaptic overgrowth and function in larval
neuromuscular junction (NMJ) [44]. Similarly, another E3
ligase, the Anaphase Promoting Complex/Cyclosome, was
shown to regulate synaptic size and synaptic transmission at
fly NMJ [45]. Over the years, many other Drosophila studies
have reported evidence of the involvement of the UPS in the
nervous system development and function [46–50].
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Figure 1:Main intracellular quality control mechanisms: Ubiquitin-Proteasome System (UPS) andAutophagy. (a) Ubiquitin is attached to target
substrates by a sequential enzymatic cascade comprised by E1 (ubiquitin-activating), E2 (ubiquitin-conjugating), and E3 (ubiquitin-ligase)
enzymes. E1 hydrolyses ATP to form an Ub-adenyl intermediate that is subsequently attached to the E1 via a thioester bond. E1-Ub transfers
the ubiquitin to the E2, which then interacts with an E3 to transfer the ubiquitin to the substrate. DUBs can cleave ubiquitin moieties to edit
ubiquitinated substrates. Protein ubiquitination regulatesmany biological processes, such as proteasomal degradation, autophagy, endosomal
trafficking, and signalling events, and also chromatin assembly, DNA transcription and repair, ribosome biogenesis and translation, cell cycle
and division, apoptosis, immunity, and organelle biogenesis. (b) Based on cargo recognition mechanisms, autophagy can be subdivided
into macroautophagy, microautophagy, and chaperone-mediated autophagy. Macroautophagy is the best-studied form of autophagy, in
which a double-membrane structure expands around and engulfs large cytosolic contents or organelles, forming an autophagosome. The
autophagosome then fuses with a lysosome and the contents are degraded. Microautophagy degrades smaller cytosolic cargo, such proteins
and tiny pieces of organelles by lysosomal invagination. CMA is involved in the degradation of unfolded or aggregated proteins that expose
a particular degradation motif (KFERQ) that is then recognised by the cytosolic chaperone heat shock cognate protein of 70 kDa (HSC70),
which interacts with lysosome-associated membrane protein type 2A leading to the unfolding and translocation of the substrate into the
lysosomal lumen where it is degraded. Several macroautophagy subtypes can be distinguished according to cargo: reticulophagy (ER),
mitophagy (mitochondria), pexophagy (peroxisome), ribophagy (ribosome), lipophagy (lipid droplets), xenophagy (intracellular pathogens
such as bacteria and virus), and aggrephagy (protein aggregates).
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Figure 2: E3 ligase types, UBE3A and Parkin. (a) Human UBE3A domain structure. Protein domain structure and amino acid numbering
refer to the isoform II. UBE3A contains an AZUL (amino-terminal Zn-finger of UBE3A E3 ligase) domain, thought to play a role in substrate
recognition, as well as a HECT domain (Homologue to E6APCarboxyl Terminus) characteristic of this family of E3 ligases, which was named
after its discovery in UBE3A, also known by the name E6AP.The ubiquitin ligating catalytic cysteine is found within this HECT domain. All
through the rest of the sequence of UBE3A only a small region known to interact with viral protein E6 has been described. (b) Parkin domain
structure. Parkin contains a N-terminal UBL domain followed by a RING-like domain (RING0) and a RBR domain.The RBR domain entails
a RING1 domain, which comprises the E2 binding site, a IBR domain, and the catalytic site encompassing RING2 domain. Amino acid
numbering is based on human sequences.
4. Studying UBE3A Function and Angelman
Syndrome (AS) Employing Drosophila
The broad use of Drosophila as a model organism since the
early years of the 20th century can be explained by its many
advantages. First of all they are suitable for genetic studies
as their fast reproductive cycle coupled to a great capacity
to provide a large amount of eggs guarantees abundant
offspring in short periods of time [51, 52]. They are easy
and cheap to handle and maintain, which makes large-scale
experiments affordable. Moreover, they only contain 4 pairs
of chromosomes: the X/Y pair of sexual genes and three pairs
of autosomal chromosomes [53], which greatly facilitates the
management and interpretation of genetic experiments. In
addition, the low genetic complexity of flies implies that there
is less redundancy and simplifies biological and mechanistic
explanations. Nevertheless, flies contain homologues for
∼75% of human genes involved in disease [54], providing
a simpler in vivo model for the study of their role in the
context of many diseases, including neurodevelopmental and
neurodegenerative diseases [55, 56].
Angelman Syndrome (AS) is a rare neurodevelopmen-
tal disorder with a prevalence of approximately 1/15.000
individuals [57], characterised by a severe intellectual and
developmental delay, movement or balance disorders, speech
impairment, and a happy demeanour that includes episodes
of frequent laughter and easy excitability [58]. Very frequently
(>80% of the cases) these symptoms are accompanied by
seizures, sleep disturbances, and microcephaly [58, 59]. The
underlying molecular cause leading to AS was discovered
to be the loss of function of the UBE3A protein in the
brain. In particular, mutations leading to truncated forms of
UBE3A were found to be enough to develop the syndrome
[29, 60]. UBE3A is a HECT-type ubiquitin E3 ligase enzyme
(Figure 2(a)) of approximately 100 kDa [61], which according
to in vitro studies catalyses attachment of K48-linked ubiq-
uitin chains to its substrates, consequently targeting them
for proteasomal degradation [62]. Interestingly, duplication
of the UBE3A gene has been associated with autism [63–65].
Many attempts have been performed in order to identify the
neuronal substrates of this enzyme, leading to the proposal of
several candidate substrates. Some of the proposed substrates
were only validated in vitro (Arc, Na+/K+ ATPase, p27,
Ring1B, Adrm1, and Rpt5) and therefore cannot be concluded
to be neuronal targets of UBE3A [66–70], while others were
identified as ubiquitinated by UBE3A using nondenaturing
immunoprecipitation approaches (Annexin A1, HHR23A,
PSMD2, and Ephexin5), which means that the ubiquitin
signal could well belong to any of the coprecipitating proteins
[71–74]. Most importantly, in vivo validation of any of these
candidates has been unsuccessful so far.
Drosophila UBE3A (Ube3a) is ubiquitously expressed
during embryogenesis and is broadly detectable in the adult
nervous system, particularly in the mushroom bodies, which
represent the key region for learning and memory [75]. Dif-
ferent flymodels have been generated to studyAS andUBE3A
duplication-based autism cases, reporting thatUbe3amutant
flies mimic characteristics of human AS [75–78]. Ube3a
null mutant flies display locomotor impairment, abnormal
circadian rhythms, and learning and memory defects, with
a particular effect on long-term memory [75]. Furthermore,
loss of Ube3a in neurons results in decreased dendritic
arborisation of larval peripheral neurons [77] and decreased
dopamine levels in adult fly brain [79]. In addition, neuronal
overexpression ofUbe3a also results in locomotion defects, in
an ubiquitin-ligase-dependent manner. Missense mutations
found in UBE3A alleles of AS patients have been reported
to act as loss-of-function mutations also in its Drosophila
homologue [75]. Fly models overexpressing Ube3a have been
shown to display comparable neurotransmission defects to
those found in mouse models of duplication 15q autism.
Overexpression of wild-type Ube3a, but not its ligase-dead
form, compromised the capacity of motor neuron axons to
support closely spaced trains of action potentials, while at the
same time increasing excitability [78]. Indeed, both overex-
pression and deficiency for Ube3a alter neurotransmission
at the neuromuscular junction in Drosophila melanogaster
3rd instar larvae, also inducing in both cases defects in
glutamatergic signalling [78]. A study investigating the role
of Ube3a in the learning ability of flies using the aversive
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phototaxis suppression assay determined that both down-
and upregulation of Ube3a are detrimental to learning in
larvae and adults [80].
5. Parkin and Parkinson’s Disease (PD),
Lessons from Drosophila
Parkinson’s Disease (PD) is the second most common neu-
rodegenerative disease after Alzheimer’s. It is considered to
affect 1% of people older than 60 years and up to 4% older
than 80 years [81, 82]. Parkinsonism englobes numerous
neurological syndromes that are mainly characterised by
resting tremor, rigidity, and postural disability. PD patients
display thesemotor symptoms, usually accompanied by other
nonmotor symptoms, including depression, constipation,
hypotension, sleep disorders, and dementia. Pathologically,
PD is mainly characterised by loss of dopaminergic neu-
rons in the substantia nigra and the presence of Lewy
bodies, intracytoplasmic proteinaceous inclusions rich in 𝛼-
synuclein [83, 84]. However, the exact pathophysiological
mechanisms leading to the disease are not clear yet and
treatments modifying disease progression are not available.
PD has been classically considered a sporadic disease linked
to aging with an unknown aetiology. However, in about 10%
of the cases, mutations in specific genes cause familial forms
of PD [85]. Mutations in the RING-Between-RING (RBR)
E3 ligase Parkin (Figure 2(b)) are the most frequent cause
of all the autosomal recessive forms [86–89]. According to
several structural studies, PD-causing mutations in Parkin
result in loss of its function by either diminishing the E3
ligase activity or affecting the correct folding of the protein
[87, 90–94].
Extensive studies performed employing Drosophila have
been critical to improve our understanding of PD patho-
physiology and Parkin function. In fact, the first hint that
Parkin was involved in mitochondrial homeostasis came
from the analysis of Parkin null flies (generated through
ablation of endogenous parkin gene through P-elementmuta-
genesis). parkin deficient flies display decreased dopamine
content and dopaminergic neurodegeneration; they also
reduced longevity, motor deficits, and male sterility [95–98].
Ultrastructural analyses showed that Parkin loss results in
abnormally swollen and disorganised mitochondria, leading
to apoptotic cell death of muscle tissue and defective sper-
matogenesis [95, 98]. Transcriptional analysis of parkin null
flies revealed that mitochondrial electron transport chain
genes, as well as genes involved in oxidative stress and innate
immune responses, were upregulated [99]. In addition, the
c-Jun N-terminal kinase pathway has been suggested to be
upregulated in dopaminergic neurons of Parkin deficient
flies, resulting in stress-mediated apoptotic neurodegenera-
tion [96]. Ever since, Parkin has been acknowledged as a neu-
roprotective factor in many in vitro and in vivo studies [100]
and, consequently, Parkin overexpression is associated with
improved mitochondrial function, increased lifespan, and
reduced proteotoxicity [101]. However, more recent studies in
flies and cells are challenging this view, as Parkin overexpres-
sion can also have deleterious effects [102–104]. Seminal stud-
ies demonstrated that another PD-associated gene, coding
for the mitochondrial kinase PINK1 [105], acts in the same
pathway upstream of Parkin. Pink1 null flies display the same
defective phenotypes as parkin null flies, and Parkin overex-
pression can rescue Pink1 loss but not vice versa [106–108].
SubsequentDrosophila genetic studies showed that Pink1 and
parkin interact with the mitochondrial fission and fusion
machinery to regulate mitochondrial dynamics [109–111].
Mammalian cell culture studies first established that
PINK1 accumulates on depolarised or damaged mitochon-
dria to recruit and activate latent overexpressed Parkin
and dispose of dysfunctional mitochondria via mitophagy
[112, 113].Thereafter, Pink1/Parkin-dependent mitophagy has
also been detected in Drosophila S2R+ cells [114] and in
vivo Drosophila models have reinforced mammalian cel-
lular discoveries. Functional studies revealed that Parkin
is phosphorylated by Pink1 in Drosophila cells, leading to
Parkin activation. Parkin phosphorylation status modifies
phenotypes typically affected in Pink1 and parkin null mutant
flies [115]; and mitochondrially located phospho-Ub (p-
Ub) rescued Pink1 null associated defects, supporting the
requirement of both ubiquitin and Parkin phosphorylation
for Parkin activation in the Pink1/Parkin pathway [116].
Nevertheless, it remains formally unproven that PINK1 and
Parkin promote mitophagy in vivo and that defects in the
disposal of dysfunctional mitochondria are involved in the
progression of the PD.
Recent findings have identified additional PD-associated
genes involved in Parkin-dependentmitophagy. Fbxo7 genet-
ically interacts with parkin in Drosophila and is involved
in PINK1/Parkin-dependent mitophagy in mammalian cells
[117]. In addition, parkin has been shown to further genet-
ically interact with LRRK2 and Vps35 in flies [118, 119],
although the functional implications are yet to be elucidated.
Beyond mitophagy, Parkin deficiency has been related to
additional dysfunctions [120]. Parkin has been reported to
ubiquitinate a broad range of substrates, including several
Lewy body components, by interacting with different E2s and
catalysing various ubiquitination types, preferentially K6-
linked polyubiquitin chains [89, 91, 92, 121–124]. However,
most of these studies were performed in vitro upon overex-
pression of the putative substrate and/or Parkin. Although
several unbiased quantitativemass spectrometry studies have
reported altered protein levels in Parkin deficient Drosophila
and mice [125–128], in vivo Parkin substrates have not been
identified so far.
6. Studying Ubiquitin Proteomics
with Drosophila
Primary discoveries are usually performed in vitro or in
cellulo, but successive in vivo confirmation is required when
translation towards human health is sought. Drosophila rep-
resents an ideal organism to study ubiquitin pathways in vivo.
Ubiquitin is highly conserved across all eukaryotes [129],
Drosophila Ub being 100% identical to the human protein.
In humans Ub is encoded by four genes: UBA52, RPS27A
(UBA80),UBB, andUBC [130, 131], while inDrosophila three
homologous genes exist: RpL40 (DUb52), RpS27A (DUb80),
and Ubi-p63E [132].
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The Drosophila proteome is predicted to contain ∼15.000
gene products, of which ∼10.000 proteins have been success-
fully identified employingmass spectrometry (MS) [133, 134].
Studying ubiquitination in vivo, however, can be very chal-
lenging, particularly in neurons. Due to the low stoichiome-
try at which ubiquitin-modified proteins are present within
cells, it is necessary to enrich the ubiquitinated fraction prior
to the MS analysis [135]. For this purpose, several purifi-
cation methods have been developed so far [66, 136–140].
Nevertheless, most of these enrichment methods require
the purification to be performed under native conditions,
copurifying contaminants and false positives [141]. Alterna-
tively, ubiquitinated peptides rather than intact ubiquitinated
proteins can be enriched prior to the MS analysis. Proteolytic
digestion of the sample with trypsin produces a characteristic
di-Gly signature in ubiquitinated peptides that is detectable
byMS [136]. Specific antibodies that recognised this ubiquitin
remnant have been developed in recent years [142] and used
for the isolation and subsequent MS-based identification
of thousands of putative ubiquitination sites in vivo [143,
144]. This approach, however, requires the proteins to be
trypsinized preventing any immunoblotting on the purified
material. Since other ubiquitin-like proteins, as well as certain
experimental conditions, also leave this di-Gly signature
in the peptides [145, 146], such orthogonal validations are
essential.
To avoid the detection of false positive ubiquitinated
proteins, an enrichment process under denaturing conditions
is preferred over the usage of physiological buffers. This has
been classically performed using poly-histidine tagging [136,
147, 148]. However, a relatively high number of endogenous
histidine-rich proteins are found in higher eukaryotes, which
are also trapped in the nickel affinity beads, resulting in
excessive background. In order to overcome these limitations,
we developed the bioUb strategy [149], based on a chemical
modification performed by biotin holoenzyme synthetase
enzymes [150] during the metabolism of fatty acids, amino
acids, and carbohydrates [151]. This biotinylation reaction is
highly specific and only few proteins are found to bemodified
with biotin in vivo [152].Theminimal length peptide that can
be efficiently biotinylated by the E. coli biotin holoenzyme
synthetase BirA is 14 amino acids long [153].This can be used
as a powerful tool for the generation of fusion proteins that
can be easily purified or detected thanks to their biotin tag.
The strategy for the in vivo isolation of ubiquitin conjugates
has so far allowed the purification and enrichment of large
amounts of ubiquitin conjugates from flies [104, 149, 154],
mice [155], and human cell lines [156].
The bioUb system relies on the in vivo expression of the
bioUb construct, which is formed by six ubiquitin-coding
sequences in tandem followed by the bacterial bifunctional
ligase/repressor BirA enzyme (Figure 3). Endogenous DUBs
digest the bioUb construct releasing BirA and ubiquitin
and mirroring the processing of endogenous ubiquitin gene
products [157]. Each ubiquitin contains a 16-amino-acid long
biotinylatable motif, which is then recognised and biotiny-
lated by BirA endogenously, resulting in a biotin-tagged
ubiquitin moiety (bioUb) that is efficiently handled by the
cascade of ubiquitin-conjugating enzymes and successfully
attached to target proteins together with the endogenous
ubiquitin. The advantage of having ubiquitinated proteins
tagged with biotin is that they can be very efficiently
and specifically purified employing avidin-conjugated beads.
Biotin-avidin interaction is one of the strongest identified
interactions in nature [158, 159], and it allows carrying out the
enrichment and washes of ubiquitinated material under very
harsh conditions, such as 8M Urea, 1M NaCl, and 2% SDS,
avoiding coisolation of nonubiquitinated interacting partners
[149]. Finally, the isolated material can be subjected to MS or
Western blot analysis [104, 149, 154–156].
On our first application of this method, our group
detected 121 ubiquitinated proteins in Drosophila neurons
during embryonic development [149], including several key
proteins involved in synaptogenesis and hence suggesting
that UPS is important for proper neuronal arrangement.
We later compared the ubiquitin landscape between devel-
oping and mature neurons in Drosophila melanogaster and
identified 234 and 369 ubiquitinated proteins, respectively
[154], some of which were found in both developmental
stages. More interestingly, certain proteins are preferentially
ubiquitinated in specific cell types during specific periods of
the Drosophila life cycle, reinforcing the importance of using
the appropriate cell type when studying ubiquitination. For
example, Ube3a was found to be active in both developing
and adult neurons, while Parkin was found to be enzy-
matically active in adult neurons only [104, 154]. Recently
we have successfully employed this approach to analyze
the ubiquitinated proteome of Drosophila under different
conditions ([104, 154] and Ramirez et al. unpublished data).
Altogether and thanks to the usage of more sensitive MS
instruments, we have identified a total of ∼1700 ubiquitinated
proteins in Drosophila neurons (Figure 4), which represent
∼11% of the total fly proteome (15.000).
7. Label-Free Quantitative
Proteomics to Identify E3 Ligase’s
Ubiquitin Substrates
The bioUb strategy can be applied to identify ubiquitin
substrates of selected E3 ligases by comparing the levels
of ubiquitinated proteins in an E3 ligase-dependent man-
ner (Figure 3). In fact, we have recently been pioneers in
deciphering the ubiquitome of flies expressing the biotin-
tagged ubiquitin in the context of either gain or loss of
function of Parkin [104] and Ube3a (Ramirez et al., 2018
manuscript under review) in adult Drosophila neuron. In
both cases, to detect the E3-ligase substrates, we followed
a label-free quantitative proteomics approach. Ubiquitinated
proteins that were enriched using the bioUb strategy in each
of the experimental conditions were independently analyzed
by MS. Resulting MS raw files were subsequently combined
for the bioinformatic analysis in which a search engine
determined the identity of the proteins in the samples as well
as their relative abundance. Consequently, those proteins,
which were found to be more abundant in the presence of the
wild-type version of the E3 ligase rather than in the presence
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Figure 3: BioUb strategy to identify ubiquitin substrates of E3 ligases in Drosophila neurons. Scheme of the strategy used to identify proteins
ubiquitinated by Parkin and Ube3a in Drosophila neurons. Flies were engineered to express endogenously precursor capable of biotinylating
ubiquitin in Drosophila photoreceptors using the GMR-GAL4 driver. This biotin modified ubiquitin (bioUb) is then incorporated within the
pool of endogenous ubiquitin, in flies that also overexpress wild-type E3 ligases (E3-WT), Parkin or Ube3a, and in their respective mutant or
ligase-dead negative controls (E3-LD). Ubiquitinated material can then be purified using Neutravidin beads and isolated material analyzed
by mass spectrometry (MS). Ubiquitinated proteins enriched in Parkin or Ube3a WT overexpressing neurons can then be identified based
on both protein LFQ levels and peptide intensities.
of the ligase-dead version of the ligase, were considered
putative E3 ligase substrates.
We successfully isolated >1.000 ubiquitinated proteins,
identifying, for example, 37 proteins whose ubiquitination
is affected by Parkin activity: 35 were more and 2 were
less ubiquitinated [104]. These include proteins associated
with the endosomal sorting complexes required for transport
(ESCRT) machinery (ALiX, Vps4), subunits of the v-ATPase
required for endosome and lysosomal acidification, andmost
importantly the PD-associated retromer component, Vps35.
We validated several of these substrates, when Drosophila
antibodies were available and interestingly showed that most
of them were monoubiquitinated by Parkin. Furthermore,
in agreement with previous mammalian cellular studies
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Figure 4: Proteomic analysis of Drosophila neuronal ubiquitome.
A cumulative number of identified ubiquitinated proteins (green)
isolated from Drosophila neurons by means of the bioUb approach
are shown. A cumulative number of proteins that appear in control
birA pulldowns, and which are therefore classified as background,
are shown in red. The first analyses (until 2013) were obtained
from fly embryonic developing neurons (using elav-GAL4 driver).
Subsequent analyses were performedwith proteins isolated from the
Drosophila photoreceptor cells (employing GMR-GAL4 driver).
[124], ubiquitin chain-linkage analysis confirmed that Parkin
preferentially catalyses K6-Ub chains in vivo.
In the case of Ube3a flies, several UPS and autophagy-
related proteins were identified to be more ubiquitinated
upon Ube3a overexpression, including two proteasomal
interacting proteins (Rpn10 and Uch-L5) earlier identified by
our lab as Ube3a substrates [160]. Our proteomic data in
neuronal tissue corroborate the findings in mammalian cell
culture that were earlier reported [70, 73]. That is, UBE3A
regulates several proteasomal subunits, which makes it likely
that further changes on the Ube3a-altered ubiquitome might
be a secondary effect. In any case, several proteins with
important roles in neuronal morphogenesis and synaptic
transmission have also been detected.
In addition, to detect E3 ligase substrates, our inves-
tigation allowed us to gather information about specific
ubiquitination sites as well as types of ubiquitination linkages.
In most proteomic studies, trypsin is the enzyme of choice
to digest proteins and obtain suitable peptides that are
further analyzed by MS. When the conjugated ubiquitin is
cleaved with trypsin, it leaves a Gly-Gly dipeptide remnant
on the conjugated lysine residues that serve as a signature
of ubiquitination and allows depicting the specific site of
modification. In agreement with in vitro studies showing that
UBE3A catalyses preferentially the attachment of K48-linked
polyubiquitin chains [62, 161], we also observed inDrosophila
that Ube3a induces K48 and K11 chains on its substrates.
Interestingly, not all the validated substrates of Ube3a seem to
be targeted for degradation [160] as one would have expected
from these ubiquitin chain types.
8. Does Parkin Regulate Something More
Than Mitochondrial Homeostasis?
Despite the fact that we identified some outer mitochondrial
membrane proteins that have been reported to be ubiqui-
tinated by Parkin during mitophagy, such as VDAC1/2/3,
TOM70, and CISD1/2, mitochondrial proteins were not
particularly enriched compared to previous studies [162,
163]. The restricted overlap between our dataset and other
previous studies indicated that results from artificial cell
culture conditions correlate with the biology of the brain
within an organism only to a certain degree. Only 8 out of
the 35 Parkin substrates identified by us have been identified
in previous studies using mitochondrial depolarisation and
mitophagy induction. In contrast, we captured the steady
state substrates of Parkin in vivo, which might be involved
in pathways beyond mitophagy. Our proteomic analysis
of Parkin substrates revealed that Parkin ubiquitinates a
wide range of proteins with no obvious functional con-
nectivity, although endocytic trafficking components, such
as Vps35, Vps4, or PDCD6IP/ALiX, were overrepresented.
Interestingly, parkin has been recently shown to genetically
interact with Vps35 in Drosophila [119], and several studies
have suggested that Parkin may be involved in endosomal
trafficking [164, 165]. Additional studies will in fact reveal
whether these substrates are functionally connected in a yet
unknown pathway. Moreover, several proteins involved in
transport of molecules and proteins; biosynthesis of proteins,
carbohydrates, and lipids; ER stress; immunity and apoptosis
were also identified in this large-scale ubiquitome study. The
heterogeneity in the nature of the putative Parkin substrates
detected suggests that the role of Parkinmight bemuchwider
than it is actually believed.
It is important to note that our Drosophila results, in
contrast to previous studies, have not required promotion of
Pink1 activity, and therefore we might have identified some
Parkin substrates that are Pink1-independent. This opens the
question of how Parkin can be activated then. It could be
possible that the cleaved cytosolic Pink1 fragment may have
a role in the activation of Parkin for other purposes than
mitophagy. It can neither be discarded that other kinases have
the ability to activate Parkin. Further studies depicting the
requirement of Pink1 for the activation and ubiquitination of
Parkin will clarify these questions.
9. Is UBE3A a Master Regulator of
the Proteasome?
The in vivo unbiased proteomics approach we have per-
formed has provided for the first time a list of putative Ube3a
substrates, whose ubiquitination is enhanced by Ube3a.
Additionally, our findings corroborate previous reports per-
formed in cells, indicating that Ube3a interacts with the
proteasome and its degradative activity, which results in the
accumulation of tens of ubiquitinated proteins of whichmany
aremost likely not direct targets of Ube3a.The ubiquitination
of proteasomal subunits by UBE3A had been previously
reported, but this Drosophila study is pioneer in reporting
in vivo evidence of their ubiquitination in neuronal cells.
Complementing previous observations, it appears that the
ubiquitination of proteasomal subunits by Ube3a/UBE3A
([70, 73, 160, 166]; Ramirez et al., 2018, manuscript under
review) places this E3 ligase as a pivotal regulator of the
proteasome and proteostasis. This finding opens a new
BioMed Research International 9
perspective in which the ubiquitination of other proteins, and
thus their levels or activity, can be affected as a downstream
effect.The existing workingmodel that UBE3A substrates are
targeted for degradation does therefore need to be revised.
10. Concluding Remarks
The bioUb approach has been successfully applied for the
MS analysis of the ubiquitin landscapes of the embryonic
nervous system and Drosophila photoreceptor cells, but it
has the potential to be implemented to any fly tissue at
any stage during the development. The nature of the bioUb
strategy allows also discerning byWestern blot whether such
identifications correspond to proteins that are mono- or
polyubiquitinated in vivo. And most importantly, for the first
time it is possible to obtain a list of candidate substrates for
any Drosophila E3 ligase in vivo.
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